Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 150%

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

Drugmaker’s melanoma shot developed with Merck delivers positive outcome in late-stage trial

The vaccine reportedly thwarted the cancer's return and spread.

Moderna vaccine cuts recurrence and spread of high-risk melanoma, raising new treatment hope  Reuters

Pharmaceutical giants Moderna and Merck said that an experimental vaccine treatment has shown signs of preventing cancer from returning or spreading in a study of high-risk melanoma patients. NBC News health reporter Aria Bendix explains what happens next.

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test  AP News

Moderna shares more than doubled after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind.

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment

Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients. Observers greeted the news with enthusiasm but noted that full data from the ongoing late-stage study has yet to be released.

A cancer vaccine developed by Merck and Moderna treating patients with melanoma showed positive and promising late-stage testing results.

Moderna stock surged after its mRNA cancer vaccine showed positive Phase 3 results with Merck’s Keytruda, boosting hopes for a new melanoma treatment.

Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.

US pharmaceutical firms Merck and Moderna announced on Wednesday encouraging results from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval. The vaccine, called intismeran autogene, showed “statistically significant and clinically meaningful improvements” for skin cancer

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday.   The positive results mean a potentially life-extending treatment is one step closer to being a

Stock prices for the American vaccine manufacturer Moderna more than doubled on Wednesday after the company reported successful results from its messenger RNA melanoma cancer vaccine.  The mRNA shot, in combination with Merck’s immunotherapy drug Keytruda, met critical benchmarks in a global late-stage clinical trial o

Moderna Shares Double on Success of mRNA Cancer Vaccine  WSJ

Moderna and Merck announced today that their personalized mRNA-based cancer vaccine, combined with Merck’s immunotherapy medication Keytruda, met initial goals in a late-stage trial.  The ongoing mRNA cancer vaccine study involves 1,137 patients with high-risk melanoma that has been surgically removed. In early results

The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.

President Trump is expected to nominate Heidi Overton, White House deputy director of domestic policy, to serve as the next FDA commissioner

Moderna shares surge as melanoma vaccine with Merck succeeds in large trial  CNN

The mRNA-based vaccine combined with Keytruda reduced melanoma recurrence in more than 1,100 patients whose cancer had been surgically removed

A JAMA Surgery study of over two million patients found that cancer treatment delays grew by more than 10 days across six disease types.